Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
26 Juin 2007 - 3:15PM
Business Wire
Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company
focused on the development and approval of drugs for the treatment
of metabolic diseases with unmet medical needs, today noted the
publication of promising results of research from three
universities regarding the potential role of insulin-like growth
factor binding protein-3 (IGFBP-3) in the prevention of blindness
among premature infants. IGFBP-3 is a key component of Insmed�s
lead drug candidate, IPLEX�, which has been approved by the U.S.
Food and Drug Administration for the treatment of a severe growth
disorder and is currently being studied as a treatment for myotonic
muscular dystrophy, HIV-associated adipose redistribution syndrome
and retinopathy of prematurity (ROP). IPLEX� is the combination of
IGFBP-3 with recombinant human insulin-like growth factor 1
(IGF-I). The new study results, published in the June 19 issue of
the Proceedings of the National Academy of Sciences, focus on the
action of IGFBP-3 in promoting normal tissue growth and preventing
ROP. Researchers at the University of Florida reported that mice
treated with IGFBP-3 showed closer-to-normal growth of retinal
vasculature than mice without IGFBP-3 in similar high-oxygen
conditions. Researchers at Harvard Medical School and the
University of Goteborg in Sweden reported similar results. In
addition, Harvard Medical School researchers, in collaboration with
researchers at the University of Goteborg, reported results of a
clinical study showing IGFBP-3 levels in infants with ROP were
lower than those of healthy babies. The researchers said these
results suggest that IGFBP-3, acting independently of IGF-I, helps
prevent oxygen-induced loss of blood-vessels and helps promote
vascular re-growth. Insmed Chairman and CEO Geoffrey Allan, Ph.D.,
commented: �These studies by researchers at three distinguished
universities mark an important scientific milestone in Insmed�s
development of IPLEX� as a treatment for ROP. They suggest that
IGFBP-3, once thought only to regulate IGF-I, actually plays a
broader role in human development and in the growth or regeneration
of human tissues. Not only is this discovery important in the fight
against ROP, but it also suggests promising avenues for research
into the treatment of other conditions associated with ischemia and
vascular damage.� About IPLEX� and ROP IPLEX� is currently in the
first phase of clinical development for the treatment of ROP, a
disease that affects an estimated 14,000 to 16,000 premature
infants each year. ROP impedes the development of the small blood
vessels in the back of the eye, leading to blindness in severe
cases. A Phase I clinical study investigating IPLEX� as a treatment
for ROP is underway at the University of Goteborg, in collaboration
with scientists at the Harvard Medical School.�Ten patients will be
enrolled with the objective of the study being to determine the
dose of IPLEX� required to increase serum IGF-I levels into the
normal physiological range. This study is expected to be completed
by the end of 2007. About Insmed Insmed is a biopharmaceutical
company focused on the development and approval of drugs for the
treatment of metabolic diseases with unmet medical needs. For more
information, please visit www.insmed.com. To be added to Insmed�s
investor lists, please contact Haris Tajyar at htajyar@irintl.com
or at 818-382-9702. Forward Looking Statements This release
contains forward-looking statements which are made pursuant to
provisions of Section 21E of the Securities Exchange Act of 1934.
Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design,
regulatory and business strategies, plans and objectives of
management and growth opportunities for existing or proposed
products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ
materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without
limitation, risks that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, the Company may
lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies
differently than the Company, competing products may be more
successful, demand for new pharmaceutical products may decrease,
the biopharmaceutical industry may experience negative market
trends and other risks and challenges detailed in the Company's
filings with the U.S. Securities and Exchange Commission, including
the Company�s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2007. Readers are cautioned not to place undue reliance
on any forward-looking statements which speak only as of the date
of this release. The Company undertakes no obligation to publicly
release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that
occur after the date of this release or to reflect the occurrence
of unanticipated events.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Août 2023 à Août 2024